Mario Sznol, MD

Professor of Medicine (Medical Oncology); Clinical Research Program Leader, Melanoma Program, Yale Cancer Center; Co-Director, Yale SPORE in Skin Cancer

Clinical Interests

  • Medical Oncology
  • Melanoma

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Melanoma Program | Prostate and Urologic Cancers Program

General Urology

Medical Oncology

Medical Oncology

Yale Medical Group

Clinical Trials

Conditions Study Title
Melanoma, skin Phase I Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients with Advanced Malignancies
Melanoma, skin A Phase 1, Open label, Dose Finding Study to Assess the Safety and Tolerability of IMCgp100, a Monoclonal T Cell Receptor anti-CD3 scFv Fusion Protein in Patients With Advanced Malignant Melanoma.
A PHASE 1b STUDY OF THE 4-1BB AGONIST PF-05082566 IN COMBINATION WITH THE PD-1 INHIBITOR MK-3475 IN PATIENTS WITH ADVANCED SOLID TUMORS
Soft Tissue Phase 1 Study of Mogamulizumab (KW-0761) in Combination with MEDI4736 and Mogamulizumab in Combination with Tremelimumab in Subjects with Advanced Solid Tumors

Edit this profile

Contact Info

Mario Sznol, MD
Patient Care Locations
Yale MelanomaSmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste 8th Floor Multispecialty Care Center

New Haven, CT 06511
Yale Melanoma ProgramSmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste 4th Floor

New Haven, CT 06511
Office Location
Fitkin Memorial Pavilion
789 Howard Avenue, Ste Suite 126

New Haven, CT 06519
Mailing Address
Yale Cancer CenterPO Box 208028
333 Cedar Street

New Haven, CT 06520-8028